Revance Therapeutics (RVNC) Stock

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the revised transaction, Revance stockholders will receive only $3.10 per share in cash, less than one-half of the August 2024 purc.

The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies. The hyaluronic acid market is poised for substantial growth over the coming years driven by its diverse applications, increasing consumer demand for beauty and wellness products, and advancements in manufacturing technologies.

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago.

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".